Consideration of supplements If you are not able to eat a balanced diet, you might benefit from taking certain supplements e.g
Whether this produces meaningfully better tolerance than simply starting at 2.5 mg remains an open question without clinical trial data to answer it
Hold off on eating for at least 2030 minutes after you inject
Common Short-term Side Effects The most common side effects occur especially when starting treatment or increasing doses, and include: Weight gain and increased appetite : Often one of the first noticeable effects Mood changes : Including irritability, anxiety, or euphoria Sleep disturbances : Insomnia or changes in sleep patterns Fluid retention : Causing swelling, particularly in the face (moon face) High blood sugar : Can unmask diabetes or worsen existing diabetes Skin changes : Including acne, easy bruising, and delayed wound healing Serious Long-term Side Effects Long-term use or high doses carry an increased risk for more serious complications: Infection Risk : Suppressed immune system increases the risk of bacterial, viral, and fungal infections Serious infections occur in 3-7% of patients on moderate doses over one year This risk may be increased in immunocompromised patients Bone and Muscle Effects : Osteoporosis affects 30-50% of long term corticosteroid therapy patients Avascular necrosis (bone tissue death due to poor blood supply) Muscle weakness and muscle pain Increased fracture risk, especially in spine and hips Heart Complications : High blood pressure Irregular heartbeat Increased risk of heart disease Fluid retention in lower legs Other Serious Effects : Vision problems including cataracts and glaucoma Severe headache Stomach ulcers Liver disease (rare but possible) Worsening mental illness or new symptoms Important Safety Considerations Taking prednisone safely requires awareness of several critical safety considerations and regular monitoring by your healthcare provider
Important Note The compounded GLP-1 telehealth industry has been under increased regulatory scrutiny
1, 2026, but will continue covering the medication for Type 2 diabetes
